This review summarizes the current knowledge and potential use of immune-modulating drugs and hypomethylating agents in preventing or treating relapse after allogeneic HCT. The authors discuss the anti-tumor properties of these agents as well as their immunomodulatory qualities, and explain how they are being used alone or in combination with adoptive immunotherapy after allogeneic HCT to enhance graft-versus-tumor effects.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Immune-Modulating Drugs, Hypomethylating Agents to Treat Relapse
Oct 2013